How Anthera Pharmaceuticals Inc (ANTH) Stacks Up Against Its Peers

We view hedge fund activity in the stock unfavorable, but in this case there was only a single hedge fund selling its entire position: 999. One hedge fund selling its entire position doesn’t always imply a bearish intent. Theoretically a hedge fund may decide to sell a promising position in order to invest the proceeds in a more promising idea. However, we don’t think this is the case in this case because only one of the 800+ hedge funds tracked by Insider Monkey identified as a viable investment and initiated a position in the stock (that fund was Citadel Investment Group).

Let’s now take a look at hedge fund activity in other stocks similar to Anthera Pharmaceuticals Inc (NASDAQ:ANTH). These stocks are Virtus Total Return Fund (NYSE:DCA), Anavex Life Sciences Corp. (NASDAQ:AVXL), Endocyte, Inc. (NASDAQ:ECYT), and Cherry Hill Mortgage Investment Corp (NYSE:CHMI). This group of stocks’ market valuations resemble ANTH’s market valuation.

As you can see these stocks had an average of 4.5 hedge funds with bullish positions and the average amount invested in these stocks was $12 million. That figure was $14 million in ANTH’s case. Endocyte, Inc. (NASDAQ:ECYT) is the most popular stock in this table. On the other hand Virtus Total Return Fund (NYSE:DCA) is the least popular one with only 4 bullish hedge fund positions. Compared to these stocks Anthera Pharmaceuticals Inc (NASDAQ:ANTH) is more popular among hedge funds. Considering that hedge funds are fond of this stock in relation to its market cap peers, it may be a good idea to analyze it in detail and potentially include it in your portfolio.

Suggested Articles:
Countries With Free Healthcare
Easiest Second Languages To Learn
Highest Paying Countries For Software Engineers

Disclosure: None